Zai Lab/$ZLAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Zai Lab

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Ticker

$ZLAB
Sector
Primary listing

Employees

1,869

Zai Lab Metrics

BasicAdvanced
$3.8B
-
-$2.03
1.03
-

What the Analysts think about Zai Lab

Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.

Bulls say / Bears say

The FDA granted Fast Track designation to ZL-1310 in May 2025, accelerating its development and opening the path toward a pivotal trial and potential accelerated approval in 2027 (Business Wire)
At ASCO 2025, Zai Lab presented updated Phase 1a/1b results for ZL-1310 showing a 67% ORR across all doses (n=33) and 79% at 1.6 mg/kg (n=14) in second-line ES-SCLC, along with a favorable safety profile, supporting plans for a registrational study in H2 2025 (Nasdaq)
Total product revenue grew by 9% year over year to $110.0 million in Q2 2025, led by record VYVGART sales of $26.5 million—up 46% sequentially—showcasing solid commercial execution (Zai Lab Q2 2025 Release)
Q2 revenue of $110.0 million missed the analyst consensus of $124.95 million, causing a 9.7% pre-market drop and raising concerns about growth prospects (Investing.com)
ZEJULA sales dropped to $41.0 million in Q2 2025 from $45.0 million a year ago due to increased competition in the PARP inhibitor segment, putting pressure on a key revenue line (Zai Lab Q2 2025 Release)
Operating loss remained high at $54.9 million (GAAP) and $34.2 million (adjusted) in Q2 2025, with profitability now expected in Q4 2025, further extending the company’s cash burn risk (Zai Lab Q2 2025 Release)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

Zai Lab Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Zai Lab Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZLAB

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs